Literature DB >> 8567949

Recombinant interferon-alpha selectively inhibits the production of interleukin-5 by human CD4+ T cells.

L Schandené1, G F Del Prete, E Cogan, P Stordeur, A Crusiaux, B Kennes, S Romagnani, M Goldman.   

Abstract

The effects of recombinant IFN-alpha on the production of IL-5 by human CD4+ T cells were first analyzed on resting CD4+ T cells purified from normal PBMC and stimulated either with a combination of PMA and anti-CD28 mAb or anti-CD3 mAb cross-linked on B7-1/CD32-transfected mouse fibroblasts. We found that IFN-alpha profoundly inhibited in a dose-dependent manner IL-5 production by resting CD4+ T cells whereas IL-10 was upregulated in both systems. The addition of a neutralizing anti-IL-10 mAb to PMA and anti-CD28 mAb upregulated IL-5 production by resting CD4+ T cells but did not prevent IFN-alpha-induced IL-5 inhibition. We then analyzed the effect of IFN-alpha on the production of cytokines by differentiated type 2 helper (Th2) CD4+CD3- cells isolated from peripheral blood of two patients with the hypereosinophilic syndrome. In both cases, IFN-alpha markedly inhibited IL-5 production while it induced mild upregulation of IL-4 and IL-10. Finally, the inhibitory effect of IFN-alpha on IL-5 production was confirmed on a panel of Th2 and Th0 clones generated in vitro. In 2 out of 6 clones, IL-5 inhibition was associated with upregulation of IL-4 and IL-10. We conclude that IFN-alpha selectively downregulates IL-5 synthesis by human CD4+ T cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8567949      PMCID: PMC507019          DOI: 10.1172/JCI118417

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  38 in total

1.  Alfa-interferon in a case of hypereosinophilic syndrome.

Authors:  P T Murphy; D F Fennelly; M Stuart; J R O'Donnell
Journal:  Br J Haematol       Date:  1990-08       Impact factor: 6.998

2.  Interferon-alpha for the hypereosinophilic syndrome.

Authors:  R M Zielinski; W D Lawrence
Journal:  Ann Intern Med       Date:  1990-11-01       Impact factor: 25.391

Review 3.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.

Authors:  T R Mosmann; R L Coffman
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

4.  Interferon-alpha for atopic dermatitis.

Authors:  R M MacKie
Journal:  Lancet       Date:  1990-05-26       Impact factor: 79.321

5.  Interleukin 5 is required for the blood and tissue eosinophilia but not granuloma formation induced by infection with Schistosoma mansoni.

Authors:  A Sher; R L Coffman; S Hieny; P Scott; A W Cheever
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

Review 6.  Interferon receptors.

Authors:  J A Langer; S Pestka
Journal:  Immunol Today       Date:  1988-12

7.  Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice.

Authors:  R L Coffman; B W Seymour; S Hudak; J Jackson; D Rennick
Journal:  Science       Date:  1989-07-21       Impact factor: 47.728

8.  Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells.

Authors:  H E Broxmeyer; L Lu; E Platzer; C Feit; L Juliano; B Y Rubin
Journal:  J Immunol       Date:  1983-09       Impact factor: 5.422

9.  Differential regulation of interleukin 4 and interleukin 5 gene expression: a comparison of T-cell gene induction by anti-CD3 antibody or by exogenous lymphokines.

Authors:  P R Bohjanen; M Okajima; R J Hodes
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

10.  Interleukin 5 and phenotypically altered eosinophils in the blood of patients with the idiopathic hypereosinophilic syndrome.

Authors:  W F Owen; M E Rothenberg; J Petersen; P F Weller; D Silberstein; A L Sheffer; R L Stevens; R J Soberman; K F Austen
Journal:  J Exp Med       Date:  1989-07-01       Impact factor: 14.307

View more
  17 in total

Review 1.  Advances in diagnosis and treatment of eosinophilia.

Authors:  Javed Sheikh; Peter F Weller
Journal:  Curr Opin Hematol       Date:  2009-01       Impact factor: 3.284

2.  Respiratory syncytial virus infection induces a subset of types I and III interferons in human dendritic cells.

Authors:  Philippa Hillyer; Viraj P Mane; Aaron Chen; Maria B Dos Santos; Lynnsie M Schramm; Rachel E Shepard; Cindy Luongo; Cyril Le Nouën; Lei Huang; Lihan Yan; Ursula J Buchholz; Ronald G Jubin; Peter L Collins; Ronald L Rabin
Journal:  Virology       Date:  2017-01-31       Impact factor: 3.616

3.  Interferon-alpha2a is sufficient for promoting dendritic cell immunogenicity.

Authors:  A Tamir; W J Jordan; M Ritter; N Habib; R I Lechler; G R Foster; G Lombardi
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

Review 4.  Regulation of effector and memory T-cell functions by type I interferon.

Authors:  Jonathan P Huber; J David Farrar
Journal:  Immunology       Date:  2011-02-14       Impact factor: 7.397

Review 5.  Mechanisms of virus induced exacerbations of asthma.

Authors:  J M Corne; S T Holgate
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

6.  Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.

Authors:  Florence Roufosse; Aurore de Lavareille; Liliane Schandené; Elie Cogan; Ann Georgelas; Lori Wagner; Liqiang Xi; Mark Raffeld; Michel Goldman; Gerald J Gleich; Amy Klion
Journal:  J Allergy Clin Immunol       Date:  2010-10       Impact factor: 10.793

7.  Interferon-α increases monocyte migration via platelet-monocyte interaction in murine intestinal microvessels.

Authors:  M Higashiyama; R Hokari; C Kurihara; T Ueda; M Nakamura; S Komoto; Y Okada; C Watanabe; A Kawaguchi; S Nagao; S Miura
Journal:  Clin Exp Immunol       Date:  2010-08-19       Impact factor: 4.330

8.  [Spectrum of hypereosinophilia syndrome based on 2 clinical case reports].

Authors:  H Nolte; U Helmchen
Journal:  Med Klin (Munich)       Date:  1998-07-15

Review 9.  Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review.

Authors:  Loïc Raffray; Loïc Guillevin
Journal:  Drugs       Date:  2018-06       Impact factor: 9.546

10.  A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis.

Authors:  H Tilg; H Vogelsang; O Ludwiczek; H Lochs; A Kaser; J-F Colombel; H Ulmer; P Rutgeerts; S Krüger; A Cortot; G D'Haens; M Harrer; C Gasche; F Wrba; I Kuhn; W Reinisch
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.